Liver Diseases
Welcome,         Profile    Billing    Logout  
 309 Companies   473 Products   473 Products   224 Mechanisms of Action   25 Trials   4900 News 


«12345678910111213...9899»
  • ||||||||||  lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
    Trial completion:  Prevention of Recurrent Hepatitis B After Liver Transplantation (clinicaltrials.gov) -  Oct 17, 2017   
    P=N/A,  N=317, Completed, 
    Recruiting --> Completed | Phase classification: P4 --> PN/A No longer recruiting --> Completed
  • ||||||||||  Enrollment change:  Gabapentin to Treat Itch in Patients With Liver Disease (clinicaltrials.gov) -  Oct 13, 2017   
    P3,  N=15, Completed, 
    Active, not recruiting --> Completed N=30 --> 15
  • ||||||||||  Enrollment closed, Trial initiation date:  Study for Consolidation Period of Chronic Hepatitis B (clinicaltrials.gov) -  Oct 13, 2017   
    P=N/A,  N=137, Active, not recruiting, 
    N=30 --> 15 Not yet recruiting --> Active, not recruiting | Initiation date: Sep 2017 --> Sep 2012
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date, Metastases:  Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer (clinicaltrials.gov) -  Sep 26, 2017   
    P1,  N=9, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jul 2017 Recruiting --> Completed | N=28 --> 9 | Trial primary completion date: Oct 2009 --> Feb 2017
  • ||||||||||  sorafenib / Generic mfg.
    Trial completion:  Sorafenib for Residue Disease After Resection With Curative Intent (clinicaltrials.gov) -  Sep 25, 2017   
    P=N/A,  N=106, Completed, 
    Recruiting --> Completed | N=50 --> 35 | Trial primary completion date: Feb 2016 --> Aug 2017 Active, not recruiting --> Completed
  • ||||||||||  simvastatin / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  Donor Simvastatin Treatment in Organ Transplantation (clinicaltrials.gov) -  Sep 19, 2017   
    P2/3,  N=84, Completed, 
    Trial primary completion date: Sep 2013 --> Dec 2015 Enrolling by invitation --> Completed | N=46 --> 84 | Trial primary completion date: Dec 2015 --> Aug 2016
  • ||||||||||  tolvaptan / Generic mfg., midodrine hydrochloride / Generic mfg.
    Trial completion:  Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites (clinicaltrials.gov) -  Sep 19, 2017   
    P2/3,  N=50, Completed, 
    Enrolling by invitation --> Completed | N=46 --> 84 | Trial primary completion date: Dec 2015 --> Aug 2016 Active, not recruiting --> Completed
  • ||||||||||  Enrollment change, Trial withdrawal, Trial primary completion date:  Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma (clinicaltrials.gov) -  Aug 31, 2017   
    P=N/A,  N=0, Withdrawn, 
    Trial primary completion date: Jun 2014 --> Nov 2015 N=238 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Dec 2016 --> Mar 2014
  • ||||||||||  Trial completion:  A2ALL-2: Adult-to-Adult Living Donor Transplant Cohort Study (clinicaltrials.gov) -  Aug 29, 2017   
    P=N/A,  N=1871, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Oct 2016 Recruiting --> Completed
  • ||||||||||  Pegasys (pegylated interferon ? -2a) / Roche
    Trial completion, Trial primary completion date:  HIDIT-II: HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis (clinicaltrials.gov) -  Aug 28, 2017   
    P2,  N=70, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2017
  • ||||||||||  folate-tubulysin (EC1456) / Novartis
    Enrollment closed, Enrollment change, Metastases:  Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Aug 23, 2017   
    P1,  N=93, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2017 Recruiting --> Active, not recruiting | N=220 --> 93
  • ||||||||||  Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date:  Portal Vein Thrombosis in Cirrhosis (clinicaltrials.gov) -  Aug 9, 2017   
    P=N/A,  N=0, Withdrawn, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> May 2017 N=78 --> 0 | Initiation date: Oct 2014 --> Oct 2013 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2017 --> Jan 2014
  • ||||||||||  baclofen / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  BacALD: Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease (clinicaltrials.gov) -  Aug 8, 2017   
    P3,  N=104, Completed, 
    N=78 --> 0 | Initiation date: Oct 2014 --> Oct 2013 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2017 --> Jan 2014 Recruiting --> Completed | N=180 --> 104 | Trial primary completion date: Aug 2015 --> Jun 2017
  • ||||||||||  Pegasys (pegylated interferon ? -2a) / Roche
    Trial completion:  Hepatitis C Antiviral Resistance in African-Americans (clinicaltrials.gov) -  Aug 2, 2017   
    P3,  N=401, Completed, 
    Recruiting --> Completed No longer recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor (clinicaltrials.gov) -  Aug 2, 2017   
    P1,  N=14, Completed, 
    No longer recruiting --> Completed Recruiting --> Completed | N=42 --> 14 | Trial primary completion date: Jul 2011 --> Jul 2013